Navigation Links
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Date:6/30/2008

al benefit of an add-on therapy in PAH patients who are already receiving an approved background therapy. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer(R)), an endothelin receptor antagonist, or sildenafil (Revatio(R)), a phosphodiesterase-5 inhibitor. The majority of patients were New York Heart Association (NYHA) Class III (~98%) of varied etiologies, including idiopathic or familial PAH (~60%), collagen vascular disease associated PAH (~30%), and PAH associated with HIV, anorexigens or other associated conditions (~10%).

The primary efficacy endpoint of the TRIUMPH-1 clinical trial was the change in six-minute walk (6MW) distance at 12 weeks measured at peak exposure, defined by the trial protocol as 10-60 minutes after administration of ITRE relative to baseline. Analysis of the TRIUMPH-1 clinical trial results confirmed an improvement in median 6MW distance of approximately 20 meters (p<0.0005 at peak exposure, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial's pre-specified statistical analysis plan), in patients receiving ITRE as compared to patients receiving only background therapy. In addition, the 6MW distance at week 12 relative to baseline at trough exposure was also significantly improved, with an estimated treatment effect of approximately 14 meters (p<0.007). Secondary endpoints related to quality of life and change in NT pro-BNP, a plasma biomarker of cardiac function, were also significantly improved in the ITRE group as compared to the group receiving only background therapy (p<0.05). Other secondary efficacy measures, including change in Borg Dyspnea Score (shortness of breath test), NYHA functional class, signs and symptoms score, and time to clinical worsening, were not significantly different between the ITRE and background therapy only groups. Safety findings were typically those associated with the well-know
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
2. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
3. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
4. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... GPM Pediatrics, reacts to a recent study, which shows how ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 According to ... severe stress are more likely than others to grow up ... pregnancy." There were two specific types of stress ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) ... sponsored by scientists at the U.S. Department of,Energy,s ... leads to rapid weight loss and reduced food ... 20, 2008 in the journal Synapse, a,prestigious peer-reviewed ...
... MONTREAL, Aug. 20 Enobia Pharma, an emerging ... bone,disorders, today announced that the first patient in ... is investigating Enzyme,Replacement Therapy (ERT) with ENB-0040 for ... bone disorder for which there is no approved,treatment., ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 2Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss 3Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 3
(Date:7/26/2014)... 2014 The European Artificial lift market report ... analysis and forecast of revenue. The artificial lift market in ... 2013 to around $5.4 billion by 2018, at a CAGR ... the TOC of European artificial lift market report, to get ... glimpse of the segmentation in European Artificial lift market, and ...
(Date:7/26/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... range of high quality party outfits. Additionally, it has ... they are now provided at discounted prices, up to ... the leading suppliers in the international market. According to ... dresses have flattering looks and fine craftsmanship. They ...
(Date:7/26/2014)... News) -- Pools can provide much-needed relief from the ... they swallow too much chlorinated water, experts warn. ... ones to get water in their mouth. Some kids ... warnings from their parents. Although swallowing a small ... parents to realize that ingesting too much can lead ...
(Date:7/26/2014)... 2014 As reported by Lauren ... based on 3 factors: smaller spaces, multi-generational access, and ... trend of 2014 lists, including this article on ... Amerec , a leading manufacturer of steam bath generators, ... due to smaller spaces and an effort to reduce ...
(Date:7/26/2014)... New York, NY (PRWEB) July 26, 2014 ... by Infosecurity magazine on July 23rd, new research by ... are starting to rewrite their playbook, now focusing more ... individuals en masse who have become increasingly wise to ... (GDF) founder and CEO/CTO, Joe Caruso, talks about ...
Breaking Medicine News(10 mins):Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Don't Let Kids Drink Pool Water 2Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6
... April 3 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. (NASDAQ: NCST ... will,step down as Vice President Finance & Administration and ... another company in a field,unrelated to any of NUCRYST,s ... search for Mr. Lurier,s successor., "On behalf of ...
... April 3 /PRNewswire-FirstCall/ - SXC Health Solutions, Corp.,("SXC" or ... leading provider of,pharmacy benefits management services, announces that Mark ... CFO, will present at the,SunTrust 37th Annual Institutional Conference ... place on Tuesday, April 15,2008 at 9:40 am Eastern ...
... FRANCISCO, Calif., April 3, 2008 ,Renovis, Inc. (Nasdaq: ... the,discovery and development of drugs for major medical ... announced today that the waiting,period under the Hart-Scott-Rodino ... without the United States Federal Trade Commission,requesting additional ...
... 2008 Medical Records Institute (MRI),announces a new ... will be announced at the TEPR 2008 opening ... This new TEPR Award is the first ... their products meet a range of EMR medicolegal,requirements, ...
... half just occasionally had too much , , THURSDAY, April 3 ... are habitual drinkers, but new research suggests that people who ... who drive while intoxicated. , When it comes to drunk ... said study author Dr. Nicole T. Flowers, a medical epidemiologist ...
... Lubbock, TX April 3, 2008 Patients with genital ... served by healthcare providers who initiate positive discussions about them, ... Womens Health. , Yet, too often, such discussions ... related to the piercings, due to healthcare providers uneasiness over ...
Cached Medicine News:Health News:NUCRYST Announces Senior Management Change 2Health News:NUCRYST Announces Senior Management Change 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements 2Health News:Alcoholics Not to Blame for All Drunk Driving Cases 2
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Microsurgical curved forceps made of titanium has curved shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Angled tying forceps made of titanium has angled shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 102 mm....
Medicine Products: